Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Chimerix Inc (NASDAQ:CMRX)

48.58
Delayed Data
As of 1:18pm ET
 -0.45 / -0.92%
Today’s Change
22.76
Today|||52-Week Range
58.04
+20.67%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$2.3B

Company Description

Chimerix, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of novel, oral antiviral therapeutics designed to address unmet medical need. Its proprietary lipid technology to unlock the potential of some of the most broad-spectrum antivirals by enhancing their antiviral activity and safety profiles in convenient, orally administered dosing regiments. The company has two nucleotide compounds in clinical development that utilize their proprietary lipid technology. Brincidofovir and CMX157. Chimerix was founded by George R. Painter and Timothy Wollaeger in April 2000 and is headquartered in Durham, NC.

Contact Information

Chimerix, Inc.
2505 Meridian Parkway
Durham North Carolina 27713
P:(919) 806-1074
Investor Relations:
(919) 287-4125

Employees

Shareholders

Mutual fund holders55.68%
Other institutional34.13%
Individual stakeholders18.45%

Top Executives

M. Michelle BerreyPresident, CEO, Director & Chief Medical Officer
Timothy W. TrostChief Financial Officer, Secretary & Senior VP
Hervé Momméja-MarinVice President-Clinical Research
William Garrett NicholsChief Medical Officer
Roberto GuzmanVice President-Compliance